Imudrops Singules 0.5% Eye Drop 5ml

Imudrops 0.5% Eye Drops contain Cyclosporine 0.5%, a calcineurin inhibitor ophthalmic emulsion manufactured by Cipla Ltd. Like Cyclomune (Sun Pharma), it treats the root cause of moderate-to-severe dry eye disease (DED) — T-cell mediated chronic inflammation of the lacrimal gland — rather than simply lubricating the ocular surface.

Cipla's Imudrops is a cost-effective alternative to originator cyclosporine preparations and contains the same active ingredient at the same concentration. Consistent twice-daily use over 3–6 months produces measurable improvements in tear production and reduction of ocular surface damage markers.

• Moderate-to-severe chronic dry eye disease (keratoconjunctivitis sicca)
• Inflammatory dry eye unresponsive to artificial tears alone
• Dry eye associated with autoimmune conditions (Sjogren's syndrome)
• Ocular surface disease with reduced Schirmer test scores

• Treats the inflammatory cause of dry eye — not just a lubricant
• Increases natural aqueous tear production with regular use
• Reduces corneal fluorescein and rose bengal staining
• Cipla manufacture ensures affordable, quality-assured treatment
• Available in single-use vials (singules) — preservative-free convenience

Common: Burning or stinging on instillation (especially early in treatment), temporary blurred vision (emulsion-related), foreign body sensation

Less common: Eye redness, discharge, increased lacrimation initially

Rare: Hypersensitivity — discontinue and consult ophthalmologist

Instil one drop in each affected eye twice daily, approximately 12 hours apart (morning and evening). For single-use vials (singules): twist open vial, instil contents in eye, discard — do not save opened vials for later use. Remove contact lenses before use; wait 15 minutes before replacing. Can be supplemented with preservative-free artificial tears (use 15 minutes apart).

Recommended dose: one drop per eye twice daily. Therapeutic benefit typically requires 3–6 months of consistent use. Do not discontinue prematurely if initial improvement is slow. Once significant improvement is achieved, some patients may be maintained on once-daily dosing under ophthalmologist guidance.

Cyclosporine inhibits calcineurin, blocking nuclear factor of activated T-cells (NFAT) transcription. This suppresses the activation and proliferation of CD4+ T-lymphocytes in the lacrimal gland and conjunctiva, reducing the cytokine-mediated inflammatory cascade (IL-1, TNF-α) responsible for lacrimal gland dysfunction. Recovery of lacrimal secretory function results in improved tear production and healthier ocular surface.

• Not for use in active ocular infections
• Single-use vials — discard each vial immediately after use; do not save partially used vials
• Remove contact lenses before instillation
• Concomitant corticosteroid eye drops require ophthalmologist supervision
• Pregnancy and lactation: limited data — use only if clearly necessary
• Shake or invert multi-dose bottles; for singules, no shaking required

Instil the missed dose as soon as remembered and continue twice-daily schedule. Do not compensate by using two drops in one session. Consistent use is key to long-term benefit.

Cyclomune (Sun Pharma) contains identical Cyclosporine 0.5% and is therapeutically equivalent. Lifitegrast 5% is an alternative immunomodulatory agent. Artificial tears and sodium hyaluronate lubricants are complementary, not replacements.

• Commit to at least 3 months of twice-daily use before evaluating efficacy
• Preservative-free singule format is ideal for sensitive eyes or frequent users
• Use artificial tears as needed in addition to Imudrops — separate by 15 minutes
• Initial burning reduces over weeks as ocular surface inflammation decreases
• Keep singules in foil packaging until use — sensitive to light

Systemic cyclosporine levels from topical use are below detection threshold — significant systemic interactions are not expected. Patients on systemic immunosuppressants should inform their ophthalmologist. Separate from other topical ophthalmic medications by 15 minutes.

Imudrops treats the chronic inflammation causing your dry eye disease. Expect initial burning that typically improves within the first few weeks. You must use these drops consistently for at least 3–6 months to see full benefit — do not stop early because of slow initial response. Each singule (single-use vial) must be discarded after use. Use alongside artificial tears for immediate symptom relief.

Q: Is Imudrops the same as Restasis or Cyclomune?

A: Yes — all three contain Cyclosporine 0.5% and are therapeutically equivalent. Imudrops is Cipla's brand, Cyclomune is Sun Pharma's, and Restasis is the originator brand by Allergan.

Q: Why are Imudrops supplied as single-use vials?

A: The single-use (singule) format is preservative-free, which is better tolerated by sensitive eyes. Each vial contains enough for one instillation in both eyes — discard after each use.

Q: When will I see improvement with Imudrops?

A: Most patients notice symptom improvement within 3–6 months of consistent twice-daily use. Schirmer test improvement (tear production) is typically measurable by month 3.

Active ingredient: Cyclosporine 0.5% (5 mg/mL). Vehicle: Castor oil emulsion. Excipients: Glycerol, polysorbate 80, carbomer, sodium hydroxide. Singule format is preservative-free.

Store below 25°C. Do not freeze. Protect from light. Keep singule vials in foil packaging until use. Discard each singule immediately after use. Keep out of reach of children.